Home › NDC Lookup › RxCUI directory › RxCUI 310261

Exemestane 25 MG Oral Tablet — RxCUI 310261

RxNorm drug concept · Semantic clinical drug
RxCUI 310261 Semantic clinical drug · SCD ● Current RxNorm concept 11 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI310261
Official nameExemestane 25 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped11
Package NDCs mapped11
Reported Medicaid activity (SDUD)35,645 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Exemestane: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Exemestane works by permanently switching off an enzyme called aromatase, which your body uses to make estrogen after menopause. Many breast cancer cells depend on estrogen to grow...
  • What exactly is exemestane doing for my breast cancer?
  • Yes, it really does matter. Taking exemestane after a meal — especially one with some fat in it — significantly improves how much of the drug your body actually absorbs. Make it a...
  • The most common side effects are hot flushes, joint pain, fatigue, headache, trouble sleeping, and increased sweating — these tend to be mild to moderate for most women. You should...
📖 Read our full Exemestane guide →

🕸️ Concept Web — How Exemestane 25 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Exemestane 25 MG Oral Tablet RxCUI 310261

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Exemestane 258494
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Aromasin 262105
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Exemestane Oral Tablet 375061
    • Exemestane Oral Product 1163788
    • Exemestane Pill 1163789
    • Exemestane Oral Tablet [Aromasin] 368218
    • Aromasin Oral Product 1170770
    • Aromasin Pill 1170771
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Exemestane 25 MG SCDC · 330333
  • Exemestane Oral Tablet SCDF · 375061
  • Exemestane Oral Product SCDG · 1163788
  • Exemestane Pill SCDG · 1163789

Brand-Name Concepts

  • Exemestane 25 MG Oral Tablet [Aromasin] SBD · 261317
  • Exemestane 25 MG [Aromasin] SBDC · 574539
  • Exemestane Oral Tablet [Aromasin] SBDF · 368218
  • Aromasin Oral Product SBDG · 1170770
  • Aromasin Pill SBDG · 1170771
  • Aromasin BN · 262105

📦 FDA Products & Package NDCs

11 products · 11 package NDCs
11 package NDCs map to RxCUI 310261 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00009-7663-04 30 TABLET in 1 BOTTLE (0009-7663-04) Aromasin Pharmacia & Upjohn Company LLC 1999-10-21
00832-0595-30 30 TABLET in 1 BOTTLE (0832-0595-30) Exemestane Upsher-Smith Laboratories, Inc. 2017-07-27
51991-0005-90 90 TABLET, FILM COATED in 1 BOTTLE (51991-005-90) Exemestane Breckenridge Pharmaceutical, Inc. 2020-11-15
59651-0516-30 30 TABLET, FILM COATED in 1 BOTTLE (59651-516-30) Exemestane Aurobindo Pharma Limited 2022-05-20
59762-2858-01 30 TABLET, SUGAR COATED in 1 BOTTLE (59762-2858-1) EXEMESTANE Mylan Pharmaceuticals Inc. 2011-04-01
63629-2056-01 30 TABLET, FILM COATED in 1 BOTTLE (63629-2056-1) Exemestane Bryant Ranch Prepack 2019-12-19
68382-0383-06 30 TABLET in 1 BOTTLE (68382-383-06) Exemestane Zydus Pharmaceuticals USA Inc. 2018-10-08
69097-0316-02 30 TABLET in 1 BOTTLE (69097-316-02) EXEMESTANE Cipla USA Inc. 2018-04-27
70771-1374-03 30 TABLET in 1 BOTTLE (70771-1374-3) Exemestane Zydus Lifesciences Limited 2018-10-08
71921-0190-33 30 TABLET, FILM COATED in 1 BOTTLE (71921-190-33) Exemestane Florida Pharmaceutical Products, LLC 2021-01-15
72603-0329-01 30 TABLET, FILM COATED in 1 BOTTLE (72603-329-01) Exemestane NorthStar Rx LLC 2025-01-01
Observed labelers: Aurobindo Pharma Limited (1) · Breckenridge Pharmaceutical, Inc. (1) · Bryant Ranch Prepack (1) · Cipla USA Inc. (1) · Florida Pharmaceutical Products, LLC (1) · Mylan Pharmaceuticals Inc. (1) · +5 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.